Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial

Fineline Cube Aug 10, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced that its interleukin-23 subunit p19 (IL-23p19) monoclonal antibody...

Company Drug

Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study

Fineline Cube Aug 9, 2022

Hangzhou-based Sciwind announced positive interim topline results from a 26-week Phase Ic/IIa clinical study of...

Company Deals

Hansoh Pharma Licenses TiumBio’s TU2670 for Endometriosis Treatment in Greater China

Fineline Cube Aug 9, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with South Korea’s...

Company Drug

Gan & Lee Pharmaceuticals’ GZR4 Wins FDA Approval for Diabetes Treatment

Fineline Cube Aug 9, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that it has received clinical trial approval...

Medical Device

GeneoDx Biotech’s Cervical Cancer Screening Kit Wins NMPA Approval

Fineline Cube Aug 9, 2022

Shanghai GeneoDx Biotech Co., Ltd, a medical diagnosis unit of Sinopharm, has announced that it...

Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty and Angelguide Approved in Colombia

Fineline Cube Aug 9, 2022

China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced...

Company Drug

HeNan Genuine Biotech Sets Azvudine Price at RMB300 per Bottle for COVID-19 Therapy

Fineline Cube Aug 9, 2022

China-based HeNan Genuine Biotech Co., Ltd has set the price of its COVID-19 therapy azvudine...

Company Deals

Sinotherapeutics Inc. to Raise RMB600m via STAR Board IPO for Generic Drug Expansion

Fineline Cube Aug 9, 2022

Sinotherapeutics Inc., a Shanghai-based generic drug developer, is set to make an initial public offering...

Policy / Regulatory R&D

CDE Issues Q&As on COVID-19 Antiviral Drug Evaluation Criteria

Fineline Cube Aug 9, 2022

The Center for Drug Evaluation (CDE) has published a list of Q&As regarding the non-clinical...

Company Medical Device

NMPA Approves BioFire Diagnostics’ Encephalitis/Meningitis Detection Kit

Fineline Cube Aug 9, 2022

The National Medical Products Administration (NMPA) website indicates that BioFire Diagnostics LLC’s encephalitis/meningitis multiple pathogen...

Company Deals R&D

BioDuro-Sundia and X-Chem Form Long-Term Partnership for Drug Discovery

Fineline Cube Aug 8, 2022

Two China-based companies, the Contract Research, Development, and Manufacturing Organization (CRDMO) BioDuro-Sundia and X-Chem, have...

Company Drug

Dizal Pharma’s Sunvozertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion

Fineline Cube Aug 8, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has unveiled the latest positive data for its...

Company Deals Digital

Hywin Holdings to Acquire Life Infinity for Health Management Expansion

Fineline Cube Aug 8, 2022

China-based wealth management firm Hywin Holdings is set to move into the health management business...

Company Drug

HutchMed’s FRESCO-2 Study for Elunate in Colorectal Cancer Meets Primary Endpoint

Fineline Cube Aug 8, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the pivotal global Phase...

Company Deals

Frontier Biotech Partners with Kindstar to Boost Anti-Infection Testing, Especially for HIV

Fineline Cube Aug 8, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar...

Company Drug

Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME

Fineline Cube Aug 8, 2022

China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...

Company Drug

Immvira’s Oncolytic Virus MVR-C5252 Receives FDA Orphan Drug Designation for Glioma

Fineline Cube Aug 8, 2022

Shenzhen-based Immvira Co., Ltd, a biotech company focused on oncolytic viruses, announced that it has...

Company Legal / IP R&D

Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief

Fineline Cube Aug 8, 2022

China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...

Hospital Policy / Regulatory

NHC Issues Notification on Medication Safety Management and Rational Drug Use

Fineline Cube Aug 8, 2022

The National Healthcare Commission (NHC) has released a notification focusing on medication safety management and...

Company Deals

Ningbo Health Gene Raises Hundreds of Millions in Series C Financing

Fineline Cube Aug 8, 2022

Ningbo Health Gene Technologies Co., Ltd, a China-based medical testing solution provider, has reportedly raised...

Posts pagination

1 … 585 586 587 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.